Comparative Efficacy of Targeted Therapies in Patients with Non-Small Cell Lung Cancer: A Network Meta-Analysis of Clinical Trials

被引:8
作者
Hoang, Tung [1 ]
Myung, Seung-Kwon [1 ,2 ,3 ,4 ]
Thu Thi Pham [5 ,6 ]
Kim, Jeongseon [1 ]
Ju, Woong [7 ,8 ]
机构
[1] Natl Canc Ctr, Grad Sch Canc Sci & Policy, Dept Canc Biomed Sci, Goyang 10408, South Korea
[2] Natl Canc Ctr, Res Inst, Div Canc Epidemiol & Management, Goyang 10408, South Korea
[3] Natl Canc Ctr Hosp, Dept Family Med, Goyang 10408, South Korea
[4] Natl Canc Ctr Hosp, Ctr Canc Prevent & Detect, Goyang 10408, South Korea
[5] Charite Univ Med Berlin, Inst Publ Hlth, Hlth Data Sci Program, D-10117 Berlin, Germany
[6] Max Delbruck Ctr Mol Med MDC, Mol Epidemiol Res Grp, D-13125 Berlin, Germany
[7] Ewha Womans Univ, Coll Med, Dept Obstet & Gynecol, Seoul 07804, South Korea
[8] Ewha Womans Univ, Coll Med, Med Res Inst, Seoul 07804, South Korea
关键词
non-small cell lung cancer; targeted therapy; network meta-analysis; CRIZOTINIB;
D O I
10.3390/jcm9041063
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This study aims to investigate the efficacy of targeted therapies in the treatment of non-small cell lung cancer (NSCLC) by using a network meta-analysis of clinical trials. PubMed, EMBASE, Cochrane Library, and Clinicaltrials.gov were searched by using keywords related to the topic on 19 September 2018. Two investigators independently selected relevant trials by pre-determined criteria. A pooled response ratio (RR) for overall response rate (ORR) and a hazard ratio (HR) for progression-free survival (PFS) were calculated based on both the Bayesian and frequentist approaches. A total of 128 clinical trials with 39,501 participants were included in the final analysis of 14 therapeutic groups. Compared with chemotherapy, both ORR and PFS were significantly improved for afatinib, alectinib, and crizotinib, while only PFS was significantly improved for cabozantinib, ceritinib, gefitinib, and osimertinib. Consistency was observed between the direct and indirect comparisons based on the Bayesian approach statistically and the frequentist approach visually. Cabozantinib and alectinib showed the highest probability for the first-line treatment ranking in ORR (62.5%) and PFS (87.5%), respectively. The current network meta-analysis showed the comprehensive evidence-based comparative efficacy of different types of targeted therapies, which would help clinicians use targeted therapies in clinical practice.
引用
收藏
页数:11
相关论文
共 24 条
  • [1] [Anonymous], FACT SHEET CANC TYP
  • [2] BRAF-mutations in non-small cell lung cancer
    Brustugun, Odd Terje
    Khattak, Asma Malik
    Tromborg, Anette Kjoshagen
    Beigi, Marzieh
    Beiske, Klaus
    Lund-Iversen, Marius
    Helland, Aslaug
    [J]. LUNG CANCER, 2014, 84 (01) : 36 - 38
  • [3] Crizotinib resistance: implications for therapeutic strategies
    Dagogo-Jack, I.
    Shaw, A. T.
    [J]. ANNALS OF ONCOLOGY, 2016, 27 : 42 - 50
  • [4] Dai L, 2017, ONCOTARGET, V8, P55731, DOI [10.18632/oncotarget.18469, 10.18632/oncotarget.18413]
  • [5] COMPARATIVE EFFECTIVENESS OF CRIZOTINIB AMONG ALK plus NSCLC PATIENTS ACROSS THE UNITED STATES, WESTERN EUROPE, AND JAPAN
    DiBonaventura, M.
    Higginbottom, K.
    Meyers, A.
    Morimoto, Y.
    Ilacqua, J.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A711 - A711
  • [6] The efficacy and safety of ALK inhibitors in the treatment of ALK-positive non-small cell lung cancer: A network meta-analysis
    Fan, Junsheng
    Fong, Tszhei
    Xia, Zengfei
    Zhang, Jian
    Luo, Peng
    [J]. CANCER MEDICINE, 2018, 7 (10): : 4993 - 5005
  • [7] Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
    Gainor, Justin F.
    Dardaei, Leila
    Yoda, Satoshi
    Friboulet, Luc
    Leshchiner, Ignaty
    Katayama, Ryohei
    Dagogo-Jack, Ibiayi
    Gadgeel, Shirish
    Schultz, Katherine
    Singh, Manrose
    Chin, Emily
    Parks, Melissa
    Lee, Dana
    DiCecca, Richard H.
    Lockerman, Elizabeth
    Huynh, Tiffany
    Logan, Jennifer
    Ritterhouse, Lauren L.
    Le, Long P.
    Muniappan, Ashok
    Digumarthy, Subba
    Channick, Colleen
    Keyes, Colleen
    Getz, Gad
    Dias-Santagata, Dora
    Heist, Rebecca S.
    Lennerz, Jochen
    Sequist, Lecia V.
    Benes, Cyril H.
    Iafrate, A. John
    Mino-Kenudson, Mari
    Engelman, Jeffrey A.
    Shaw, Alice T.
    [J]. CANCER DISCOVERY, 2016, 6 (10) : 1118 - 1133
  • [8] Novel Targets in Non-Small Cell Lung Cancer: ROS1 and RET Fusions
    Gainor, Justin F.
    Shaw, Alice T.
    [J]. ONCOLOGIST, 2013, 18 (07) : 865 - 875
  • [9] Targeting the MET gene for the treatment of non-small-cell lung cancer
    Gelsomino, F.
    Facchinetti, F.
    Haspinger, E. R.
    Garassino, M. C.
    Trusolino, L.
    De Braud, F.
    Tiseo, M.
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2014, 89 (02) : 284 - 299
  • [10] Efficacy of Crizotinib, Ceritinib, and Alectinib in ALK-Positive Non-Small Cell Lung Cancer Treatment: A Meta-Analysis of Clinical Trials
    Hoang, Tung
    Myung, Seung-Kwon
    Pham, Thu Thi
    Park, Boyoung
    [J]. CANCERS, 2020, 12 (03)